Ieq Capital LLC Purchases New Position in Haemonetics Corporation $HAE

Ieq Capital LLC bought a new stake in Haemonetics Corporation (NYSE:HAE) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 17,295 shares of the medical instruments supplier’s stock, valued at approximately $1,297,000.

Several other large investors have also recently added to or reduced their stakes in HAE. AQR Capital Management LLC grew its position in shares of Haemonetics by 48.6% in the fourth quarter. AQR Capital Management LLC now owns 3,163,104 shares of the medical instruments supplier’s stock valued at $253,523,000 after purchasing an additional 1,034,226 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its stake in Haemonetics by 994.7% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,380,102 shares of the medical instruments supplier’s stock valued at $110,615,000 after purchasing an additional 1,254,035 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Haemonetics by 21.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,326,057 shares of the medical instruments supplier’s stock worth $74,731,000 after acquiring an additional 233,119 shares during the period. North Peak Capital Management LLC raised its stake in Haemonetics by 204.4% during the fourth quarter. North Peak Capital Management LLC now owns 1,102,992 shares of the medical instruments supplier’s stock worth $88,405,000 after purchasing an additional 740,626 shares during the period. Finally, Fort Washington Investment Advisors Inc. OH raised its position in shares of Haemonetics by 17.3% in the 1st quarter. Fort Washington Investment Advisors Inc. OH now owns 841,017 shares of the medical instruments supplier’s stock worth $47,400,000 after buying an additional 124,020 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have weighed in on HAE. Mizuho upped their price target on Haemonetics from $85.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. Wall Street Zen upgraded shares of Haemonetics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Barrington Research upped their price target on shares of Haemonetics from $95.00 to $118.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 19th. Citigroup boosted their target price on Haemonetics from $79.00 to $92.00 and gave the stock a “neutral” rating in a report on Friday, August 7th. Finally, BTIG Research upped their price objective on shares of Haemonetics from $96.00 to $110.00 and gave the company a “buy” rating in a research note on Tuesday, August 18th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $97.56.

Haemonetics Price Performance

NYSE:HAE opened at $106.78 on Thursday. Haemonetics Corporation has a 12-month low of $47.31 and a 12-month high of $109.57. The firm has a market capitalization of $4.86 billion, a price-to-earnings ratio of 52.34, a P/E/G ratio of 2.17 and a beta of 0.52. The stock’s 50 day moving average price is $83.68 and its two-hundred day moving average price is $69.40. The company has a quick ratio of 1.91, a current ratio of 3.08 and a debt-to-equity ratio of 1.40.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $1.14 EPS for the quarter, beating the consensus estimate of $1.08 by $0.06. The firm had revenue of $339.38 million for the quarter, compared to analyst estimates of $327.86 million. Haemonetics had a net margin of 7.12% and a return on equity of 27.55%. The business’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same period last year, the firm earned $1.10 EPS. On average, analysts anticipate that Haemonetics Corporation will post 5.29 earnings per share for the current year.

Haemonetics News Summary

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Zacks raised its FY2027 EPS estimate to $5.27 from $5.20, increased Q4 2027 to $1.46 from $1.42, and lifted Q4 2028 to $1.46 from $1.41.
• Positive Sentiment: Longer-term projections also improved modestly: Q1 2029 EPS rose to $1.41 from $1.33, while FY2029 increased to $6.20 from $6.19. These changes suggest some confidence in Haemonetics’ longer-term earnings growth.
• Neutral Sentiment: The overall revision pattern is mixed, with increases in some later-period estimates offset by reductions in other quarters. Zacks’ FY2028 forecast is now $5.67, and its FY2027 estimate of $5.27 remains close to the $5.28 current-year consensus.
• Negative Sentiment: Zacks lowered several estimates, including Q2 2027 EPS to $1.30 from $1.32, Q3 2027 to $1.36 from $1.37, Q1 2028 to $1.27 from $1.31, Q2 2028 to $1.44 from $1.45, Q3 2028 to $1.50 from $1.52, and FY2028 to $5.67 from $5.69.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.